EFdA Nucleoside Inhibitor for Less Frequent HIV Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV treatment regimens require daily dosing, which can be burdensome and may lead to adherence issues, while there is a need for less frequent dosing options for both treatment and prophylaxis of HIV infection.
Innovation Solution
The use of 4′-ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) or 4′-ethynyl-2-chloro-2′-deoxyadenosine (ECdA) as a nucleoside reverse transcriptase inhibitor, administered via oral or parenteral routes, with dosing regimens that include once-weekly or less frequent intervals to provide effective HIV suppression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If daily dosing is used for HIV treatment, then viral suppression is maintained, but patient adherence is compromised and treatment burden increases
Solution Approach 1:
The patent changes the dosing frequency parameter from daily to less frequent intervals (e.g., every other day, every 3 days, weekly, bi-weekly, monthly) while maintaining viral suppression through optimized dose amounts. This parameter change resolves the contradiction by reducing treatment burden and improving adherence without compromising viral control.
Solution Approach 2:
The patent introduces flexible dosing schedules that can be dynamically adjusted based on patient needs and viral load levels. The dosing interval can vary from every other day to monthly, allowing the treatment regimen to adapt to different patient circumstances while maintaining effective viral suppression.
2Reliability
If daily dosing is used for HIV treatment, then effective viral suppression is achieved, but treatment complexity and burden increase
Solution Approach 1:
The patent simplifies the dosing regimen by changing the frequency parameter from daily to less frequent intervals. This reduces the complexity of the treatment schedule while maintaining viral suppression, making the regimen easier to manage and less prone to errors.
3Ease of operation
If less frequent dosing is used, then patient adherence improves, but dosing interval must be extended to maintain viral suppression
Solution Approach 1:
The patent optimizes the dose amount parameter to compensate for reduced dosing frequency. By adjusting the dose size and utilizing long-acting formulations, the patent maintains effective viral suppression even with extended dosing intervals, resolving the contradiction between adherence and dosing frequency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
EFdA and ECdA demonstrate potent antiviral activity with long intracellular half-lives, allowing for effective HIV suppression with less frequent dosing, which can improve patient adherence and long-term treatment success.
Implementation Method 1
NRTIs and nucleotide reverse transcriptase inhibitors (NtRTIs such as tenofovir) enter into obligate intracellular anabolic pathways for conversion to active phosphorylated forms
Implementation Method 2
4′-Ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) is a nucleoside reverse transcriptase inhibitor that blocks HIV-1 and SIV viral replication
Implementation Method 3
Both compounds are metabolized in cells to their active triphosphate anabolite which inhibits HIV reverse transcriptase
Implementation Method 4
EFdA and ECdA retain a 3′-OH group and act as a chain terminator by preventing translocation of the primer:template in the reverse transcriptase (RT) active site
Data Source
AI summary
The present invention is directed to methods for inhibition of HIV reverse transcriptase, treatment of infection by HIV, prophylaxis of infection by HIV, and the treatment, prophylaxis and/or delay in the onset or progression of AIDS or ARC by administering a compound of structural Formula Ior a pharmaceutically acceptable salt or co-crystal thereof, wherein X is —F or —Cl, less frequently than once daily.